Merck will follow big pharma’s standard MO of looking elsewhere to bring new assets in-house, CEO Kenneth Frazier said at this week’s J.P. Morgan healthcare investing conference.
“As we move into 2015, we will continue to rigorously sharpen our focus, and find best external assets to fuel growth,” Frazier said, adding that Merck is on track to reduce R&D costs by $2.5 billion.
Here are the pharma behemoth’s four areas of strategic growth:
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
1. Diabetes – with continued marketing heft for its top-seller, Januvia
2. Vaccines – with a particular focus on the launch of shingles prophylactic Zostavax
3. Hospital acute care – with a focus on developing antimicrobials, particularly newere assets from the Cubist acquisition
4. Oncology – with aims to extend the indications associated with Keytruda
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
These fields represent about 40 percent of Merck’s biz today – and “while we’ll continue to support other areas, these will receive higher levels of resources and attention,” Frazier said.
